[1]
|
Tao, Y., Huang, C., Liu, M., et al. (2019) Short-Term Effect of Intravitreal Conbercept Injection on Major and Macular Branch Retinal Vein Occlusion. The Journal of International Medical Research, 47, 1202-1209.
https://doi.org/10.1177/0300060518819613
|
[2]
|
Sun, Z., Yang, Y., Lin, B., et al. (2023) Comparative Efficacy of Aflibercept and Ranibizumab in the Treatment of Age-Related Macular Degeneration with Retinal Pigment Epithelial De-tachment: A Systematic Review and Network Meta-Analysis. BMC Ophthalmology, 23, Article No. 473. https://doi.org/10.1186/s12886-023-03214-7
|
[3]
|
Xing, Q., Dai, Y., Huang, X., et al. (2023) Comparison of Effi-cacy of Conbercept, Aflibercept, and Ranibizumab Ophthalmic Injection in the Treatment of Macular Edema Caused by Retinal Vein Occlusion: A Meta-Analysis. International Journal of Ophthalmology, 16, 1145-1154. https://doi.org/10.18240/ijo.2023.07.21
|
[4]
|
Arevalo, J.F. (2013) Diabetic Macular Edema: Current Management 2013. World Journal of Diabetes, 4, 231-233.
https://doi.org/10.4239/wjd.v4.i6.231
|
[5]
|
马爱霞. 康柏西普对比雷珠单抗治疗老年黄斑变性的药物经济学评价[J]. 中国药物经济学, 2018, 13(9): 27-31.
|
[6]
|
Xing, P., Meng, B., Hu, X., et al. (2023) Switching to Conbercept in Diabetic Macular Edema after Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab. Clinical Ophthalmology (Auckland, NZ), 17, 3491-3497.
https://doi.org/10.2147/OPTH.S431145
|
[7]
|
Wang, Y., Zhou, C., Li, R., et al. (2023) The Role of Serum Metrics in Anti-VEGF Treatment for Macular Edema Induced by Retinal Vein Occlusion. BMC Ophthalmology, 23, Article No. 173.
https://doi.org/10.1186/s12886-023-02921-5
|
[8]
|
Wu, Z., Zhao, J., Lam, W., et al. (2021) Comparison of Clinical Outcomes of Conbercept versus Ranibizumab Treatment for Retinopathy of Prematurity: A Multicentral Prospective Randomised Controlled Trial. British Journal of Ophthalmology, 106. https://doi.org/10.1136/bjophthalmol-2020-318026
|
[9]
|
Sinha, Y., Trehan, H., Kurumkattil, R., et al. (2023) A Quantitative Evaluation of the Effect of Meals on Macular Thickness in Diabetic Patients with Diabetic Macular Edema. Oman Journal of Ophthalmology, 16, 509-515.
|
[10]
|
Zhan, H., Zhou, J., Zhang, J., et al. (2023) Conbercept Combined with Laser Photocoagulation in the Treatment of Diabetic Macular Edema and Its Influence on Intraocular Cytokines. World Journal of Diabetes, 14, 1271-1279.
https://doi.org/10.4239/wjd.v14.i8.1271
|
[11]
|
Teo, Z., Tham, Y., Yu, M., et al. (2021) Global Prevalence of Dia-betic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-Analysis. Ophthalmology, 128, 1580-1591.
https://doi.org/10.1016/j.ophtha.2021.04.027
|
[12]
|
Li, F., et al. (2018) One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema. Current Eye Research, 43, 218-223. https://doi.org/10.1080/02713683.2017.1379542
|
[13]
|
李彬彬, 谭美华, 殷章亮. 康柏西普不同给药方案治疗有临床意义的糖尿病性黄斑水肿疗效比较[J]. 国际眼科杂志, 2022, 22(1): 130-134.
|
[14]
|
吴乔伟, 黄珍, 闫明, 等. 康柏西普不同给药方案治疗糖尿病黄斑水肿的疗效对比[J]. 中华眼底病杂志, 2022, 38(1): 40-48.
|
[15]
|
Volkmann, I., Knoll, K., Wiezorrek, M., et al. (2020) Individualized Treat-and-Extend Regime for Optimization of Real-World Vi-sion Outcome and Improved Patients’ Persistence. BMC Ophthalmology, 20, Article No. 122.
https://doi.org/10.1186/s12886-020-01397-x
|
[16]
|
Thomas, C.J., Mirza, R.G. and Gill, M.K. (2021) Age-Related Macular Degeneration. The Medical Clinics of North America, 105, 473-491. https://doi.org/10.1016/j.mcna.2021.01.003
|
[17]
|
Ruggeri, M., Toto, L., D’aloisio, R., et al. (2023) Long-Term Follow-Up of Brolucizumab in Macular Neovascularization. Ophthalmic Research, 66, 1383-1391. https://doi.org/10.1159/000534894
|
[18]
|
Pauleikhoff, D., Gunnemann, M., Ziegler, M., et al. (2023) Morphological Changes of Macular Neovascularization during Long-Term Anti-VEGF-Therapy in Neovascular Age-Related Macular Degeneration. PLOS ONE, 18, e0288861.
https://doi.org/10.1371/journal.pone.0288861
|
[19]
|
Lee, J., Kim, K., Kim, E., et al. (2023) Seven-Year Outcomes of Combined Treatment of Anti-Vascular Endothelial Growth Factor with Photodynamic Therapy for Polypoidal Choroidal Vasculopathy; According to Polypoidal Lesion Regression. BMC Ophthalmology, 23, Article No. 511. https://doi.org/10.1186/s12886-023-03264-x
|
[20]
|
Jin, E., Bai, Y., Luo, L., et al. (2019) Serum Levels of Vascular Endothelial Growth Factor Before and after Intravitreal Injection of Ranibizumab or Conbercept for Neovascular Age-Related Macular Degeneration. Retina, 37, 971-977.
|
[21]
|
Liu, K., Song, Y.P., Xu, G.Z., et al. (2019) Conbercept for Treatment of Neovascular Age-Related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. American Journal of Ophthalmology, 197, 156-167.
|
[22]
|
Gao, L., Liu, J., Zhang, P., et al. (2020) Clinical Outcomes of 1+PRN and 3+Q3M Regimens of Intravitreal Conbercept Injection for Exudative Age-Related Macular Degeneration. Scientific Reports, 10, Article No. 8010.
https://doi.org/10.1038/s41598-020-65000-5
|
[23]
|
Chen, X., Li, C., Ding, G., et al. (2023) Clinical Efficacy and Changes of Serum VEGF-A, VEGF-B, and PLGF after Conbercept Treating Neovascular Age-Related Macular Degen-eration. International Journal of Ophthalmology, 16, 1489-1495. https://doi.org/10.18240/ijo.2023.09.16
|
[24]
|
Wang, X. and Wang, P. (2023) Spectral-Domain Optical Coherence Tomography Combined with Electroretinography in the Assessment of Conbercept for Neovascular Age-Related Macular Degeneration: A Preliminary Study. Frontiers in Neuroscience, 17, Article ID: 1179421. https://doi.org/10.3389/fnins.2023.1179421
|
[25]
|
Hattenbach, L.O., Chronopoulos, A. and Feltgen, N. (2022) Reti-nal Vein Occlusion: Intravitreal Pharmacotherapies and Treatment Strategies for the Management of Macular Edema. Die Ophthalmologie, 119, 1100-1110.
https://doi.org/10.1007/s00347-022-01735-y
|
[26]
|
Huang, Y., Linghu, M., Hu, W., et al. (2022) Conbercept Im-proves Macular Microcirculation and Retinal Blood Supply in the Treatment of Nonischemic Branch Retinal Vein Occlu-sion Macular Edema. Journal of Clinical Laboratory Analysis, 36, e24774. https://doi.org/10.1002/jcla.24774
|
[27]
|
严然, 高新晓, 朱思泉. 康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效[J]. 临床药物治疗杂志, 2020, 18(12): 43-47.
|
[28]
|
Yang, K.B., Sun, X.Y., Sun, L.P., et al. (2020) Aqueous Humor Cytokine Levels and Rebound Macular Edema Following Conbercept Treatment in Patients with Central Retinal Vein Occlusion. Retina, 41, 834-843.
https://doi.org/10.1097/IAE.0000000000002918
|
[29]
|
Wei, Q., Sun, T., Wan, Z., et al. (2020) Cytokine and Chemokine Profile Changes in Patients after Intravitreal Conbercept Injection for Center Macular Edema Due to Branch Retinal Vein Occlusion. American Journal of Translational Research, 12, 4001-4008.
|
[30]
|
Sun, Z., Zhou, H., Lin, B., et al. (2017) Efficacy and Safety of Intravitreal Conbercept Injections in Macular Edema Secondary to Retinal Vein Occlu-sion. Retina, 37, 1723-1730. https://doi.org/10.1097/IAE.0000000000001404
|
[31]
|
Zeng, H., Liu, Q., Li, X., et al. (2020) One-Year Efficacy of Intravitreal Conbercept Injection for Macular Oedema Secondary to Central Retinal Vein Occlusion in Chinese Patients. Eye (London, England), 34, 1459-1464.
https://doi.org/10.1038/s41433-020-0827-y
|
[32]
|
Ye, Y., Deng, Y., Huang, Z., et al. (2023) Long-Term Outcomes of Anti-VEGF Treatment with 5+PRN Regimen for Macular Edema Due to Central Retinal Vein Occlusion. Internation-al Journal of Ophthalmology, 16, 1642-1650.
https://doi.org/10.18240/ijo.2023.10.13
|